Femoral Artery Blood Flow During Rest and One-leg Knee Extensor Exercise in Patients With COPD
COPD-DOPPLER
1 other identifier
interventional
32
1 country
1
Brief Summary
Doppler ultrasound is generally considered to provide reliable femoral blood flow measurements between rest and exercise, and the blood flow response to exercise is widely believed to be reduced in patients with chronic obstructive pulmonary disease (COPD). However, the test-retest reliability of the method during one-leg knee extensor exercise has not previously been compared between matched healthy individuals.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Nov 2023
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 12, 2023
CompletedFirst Posted
Study publicly available on registry
November 18, 2023
CompletedStudy Start
First participant enrolled
November 21, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 12, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 12, 2024
CompletedJanuary 19, 2024
January 1, 2024
2 months
November 12, 2023
January 17, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Between-day smallest real difference (SRD) for femoral blood flow at rest and at each relative exercise intensity in COPD vs. healthy controls
Doppler ultrasound measured blood flow during one leg knee extensor exercise with different intensities.
Measured at day 1 and day 2
• Between-day coefficient of variance (CV) for femoral blood flow at rest and at each relative exercise intensity in COPD vs. healthy controls (co-primary)
Doppler ultrasound measured blood flow during one leg knee extensor exercise with different intensities.
Measured at day 1 and day 2
Secondary Outcomes (3)
Femoral blood flow response to exercise at each relative exercise intensity in COPD vs. healthy controls (key secondary)
Measured at day 1 and day 2
Between-day smallest real difference (SRD) for femoral blood flow at rest and at each absolute exercise intensity in COPD vs. healthy controls
Measured at day 1 and day 2
• Between-day coefficient of variance (CV) for femoral blood flow at rest and at each absolute exercise intensity in COPD vs. healthy controls (co-primary)
Measured at day 1 and day 2
Study Arms (2)
COPD-patients
EXPERIMENTALThe participants will be instructed to abstain from caffeine, nicotine, alcohol, and strenuous exercise all known to affect blood flow to the limb for 12 hours prior to the study day. After being placed on the one-leg kicking chair, baseline measurements will be performed, followed by passive leg movement for 2 minutes. Then participants will perform one-legged knee-extension exercise at submaximal intensity, first at 10% and then at 20% of the previously measured WLpeak, remaining 3.5 minutes at each level, while femoral blood flow is measured. This study day will be repeated within 2-10 days.
Matched healthy volunteers
EXPERIMENTALThe participants will be instructed to abstain from caffeine, nicotine, alcohol, and strenuous exercise all known to affect blood flow to the limb for 12 hours prior to the study day. After being placed on the one-leg kicking chair, baseline measurements will be performed, followed by passive leg movement for 2 minutes. Then participants will perform one-legged knee-extension exercise at submaximal intensity, first at 10% and then at 20% of the previously measured WLpeak, remaining 3.5 minutes at each level, while femoral blood flow is measured. This study day will be repeated within 2-10 days.
Interventions
Doppler ultrasound is used while participants exercise according to the one-legged knee-extensor exercise model
Eligibility Criteria
You may qualify if:
- Men and women
- years
- COPD (GOLD stage I to III)
- Forced expiratory volume in 1 sec (FEV1)/forced vital capacity ratio (FVC) \< 0.8, FEV1 \< 90% of predicted value
- Modified Medical Research Council score (mMRC 0 - 3) Resting arterial oxygenation \> 90%
You may not qualify if:
- Symptoms of ischaemic heart disease
- Known heart failure
- Claudication
- Symptoms of disease within 2 weeks prior to the study
- Participation in pulmonary rehabilitation within 6 months
- Known malignant disease
- Pregnancy
- Unstable cardiac arrhythmic disease
- Renal or liver dysfunction
- Men and women
- years
- Normal FEV1, FVC, FEV1/FVC, and single-breath diffusion capacity
- Same sex, age (± 3 years) as the COPD patients
- Known chronic lung disease
- Known ischaemic heart disease
- +7 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Center for Aktiv Sundhed (CFAS), Rigshospitalet, Copenhagen, Denmark.
Copenhagen, København Ø, 2100, Denmark
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- BSc(Med) and principal investigator at Center for Aktiv Sundhed (CFAS), Rigshospitalet.
Study Record Dates
First Submitted
November 12, 2023
First Posted
November 18, 2023
Study Start
November 21, 2023
Primary Completion
January 12, 2024
Study Completion
January 12, 2024
Last Updated
January 19, 2024
Record last verified: 2024-01